Education
About Us
Working with TipRanks
Follow Us
Replimune Group (REPL)
:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.68 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)16.12M
Market Cap
$491.74M
Enterprise Value$0.00
Total Cash (Recent Filing)$483.80M
Total Debt (Recent Filing)$76.17M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Oct 30, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding77,807,175
10 Day Avg. Volume35,585,293
30 Day Avg. Volume16,119,206
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$4.29Price Target Upside-32.12% Downside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Product PotentialTUDRIQEV is likely to be a successful first therapeutic in Replimune's skin cancer franchise, given IGNYTE data in melanoma, which significantly de-risked.
Bears Say
Clinical TrialsReplimune will likely need to re-run its clinical studies to get to approval and may not have enough cash on its books to get there, in our view.
Financial OutlookAnalysts adjust the rating of shares to Underperform and cut the target price to $2/share, reflecting uncertainty at the new FDA and the cash required to re-run studies.
Market Entry DelaysRP1's potential U.S. market entry has been pushed back to 2029, while its probability of approval has been lowered to 50% from the prior 95%.
Regulatory ChallengesThe FDA has issued a Complete Response Letter regarding the Biologics License Application for RP1 in anti-PD-1-failed melanoma, which is likely a negative surprise for many investors.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $2.68 and its highest was $17.00 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $491.74M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Aug 07, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.794 by -$0.156.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Overvalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate is -0.75.
How many shares outstanding does Replimune Group have?
Replimune Group has 77,807,175 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.794. Following the earnings report the stock price went up 3.546%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.29 (-32.12% Downside)
$4.29 (-32.12% Downside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 13.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $603.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 132.7%
Last 30 Days ▲ 132.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.76%
12-Months-Change
Fundamentals
Return on Equity
-62.58%
Trailing 12-Months
Asset Growth
13.04%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, emphasizing significant progress towards the approval and launch of RP1 with strong clinical data and a well-prepared commercial strategy. However, increased expenses and losses, along with a lengthy enrollment period for a confirmatory trial, present challenges that need to be addressed.View all REPL earnings summariesREPL Stock 12 Month Forecast
Average Price Target
$4.29
▼(-32.12% Downside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---